Whole-exome sequencing identifies a novel somatic mutation in MMP8 associated with a t(1;22)-acute megakaryoblastic leukemia Leukemia(2014) 28, 945-948; Acute myeloid leukemia (AML) is a clonal hematopoietic disease caused by both inherited and acquired genetic alterations. Conventional cytogenetic analysis reveals chromosomal aberrations in B50% of AML cases. These chromosomal rearrangements promote leukemia by affecting cell proliferation, differentiation and/or survival. In addition to these genetic alterations, cooperating mutations are required for leukemogenesis. 1-3 Among the subtypes of AML, pediatric-acute megakaryoblastic leukemia (AMKL) is primarily associated with three cytogenetic subtypes: one with trisomy 21 plus a mutation of GATA1, one with the t(1;22) translocation 4,5 and a third recently reported recurrent cryptic inversion of chromosome 16 (inv(16)(p13.3q24.3)). 6,7 AMKL with t(1;22) is typically an aggressive disease, presenting in early infancy with a median survival of just 8 months. Translocation between chromosomes 1p13 and 22q13 results in the fusion gene, RBM15-MKL1. The mechanism(s) by which the fusion protein promotes leukemia is unknown. RBM15-MKL1 knock-in mice develop AMKL, but with delayed onset (16-18 months) and incomplete penetrance. 8 Induced RBM15-MKL1 overexpression in cell lines causes cell death. 9 Together, these findings suggest that RBM15-MKL1 requires cooperating mutations to induce AMKL. To identify potential cooperating mutations in t(1;22) AMKL, we performed a whole-exome capture followed by next-generation sequencing in diagnostic and remission samples from a t(1;22)-AMKL patient. An 11-week-old boy presented with loss of appetite and fussiness. Samples of bone marrow and peripheral blood were obtained at presentation. Morphological and immunophenotypic analyses were performed at the UC Davis Pathology Department according to standard protocols. FISH and cytogenetic analyses were performed by the Mayo Clinic Laboratory (Children's Oncology Group designated laboratory). The remaining diagnostic sample was frozen. The blood had a white blood cell count of 38 000/mm 3 , hemoglobin of 6.1 g/dl and platelet count of 99 000/mm 3 . The peripheral blood smear showed immature blast cells (18% of white blood cells). Bone marrow examination revealed severe fibrosis (Figures 1a and b) . Peripheral blood immunophenotyping showed 15% leukemic blasts based on CD45 expression and Side Scatter profile. These cells expressed
and no difference in quality was seen in the further analyses, including exome capture, PCR amplification and sequencing. To delineate the breakpoints on chromosomes 1 and 22, PCR was performed as described. 5 Multiplex PCR was performed with combinations of primers (as shown in Figure 1d ) to narrow down the breakpoint region. When single primer pairs were then used for individual PCR reactions, no amplification occurred with OTT4 and In4.1-3, but 0.5 and 2.2 kb products were amplified with OTT4 and In4.4 and In4.5, respectively (Figure 1e ) confirming that the translocation occurred between chromosome 1 and 22 with the breakpoint in intron 1 of OTT and intron 4 of MKL1.
To identify potential cooperating mutations in this patient sample, exome capture followed by deep sequencing was performed on the leukemia and remission blood samples from the patient. A total of 88 807 512 and 79 716 978 reads were obtained from the leukemic and remission samples, respectively ( Supplementary Table S2 ). Picard software identified and removed PCR duplicates (14.0% of the leukemia sample and 9.4% of the blood sample). About 96% of the remaining unique reads from both samples mapped to only one location in the genome with B94% of targeted bases with 410 Â coverage ( Supplementary  Table S2 ). Varscan identified 97 926 single nucleotide variations (SNVs) with a minimum variant frequency in the sample of 40.02 and minimum average quality score of 420. Of these variants, 22 326 were called somatic variations, which were filtered to require o0.2 P-value so that the SNV was different in leukemia vs remission, leaving 4580. Of the 4580 SNV, 2123 were in genic regions and 95.3% were classified as coding variants, with 75.2% being non-synonymous. SIFT (sorting intolerant from tolerant) predicted 36.0% and 62.9% of the coding variants as damaging and tolerated variations, respectively ( Supplementary Table 3 ). Of 1956 coding variants, 1876 were novel SNPs based on dbSNP. Of the 1956, 377 SNVs remained after further filtering to require o0.05 P-value and damaging/tolerated SIFT predictions, and to exclude known dbSNPs. To overcome the low blast purity (15% of cells), we used a less stringent filter to maximize the chances of detecting variations within the leukemic cells, which resulted in false positive variants from the initial analysis. Therefore, it was necessary to carefully inspect the reads manually using the integrated genomics viewer. After manual inspection of the 377 SNVs for base quality displayed in the integrated genomics viewer (IGV v2.1, 10 ), we found 12 variants to be likely candidates and performed further validation for these 12 variants (Table 1) . Neither known AML-associated mutations nor mutations in tumor suppressor genes were found. However, small indels would not be detectable in our data owing to the low blast percentage.
To validate the candidate mutations, Sanger sequencing was performed, but proved to be technically challenging owing to the low percentage of blasts. By Sanger sequencing, the expected peak for the variant alleles was not distinguishable except for one in HERC2 that proved to exist in both the leukemic and remission samples at B50%, suggesting a unique SNP in the patient (data not shown). To improve the sensitivity, 10 of the remaining 11 variants were further validated with droplet digital PCR (one failed in the assay design because of repetitive Accepted article preview online 25 October 2013; advance online publication, 22 November 2013 sequences and a high GC content). Despite multiple repetitions and assessment using modified primer pairs, of the 10 variants assessed using droplet digital PCR, only MMP8 was validated (Supplementary Figure S1 ), whereas the other nine variants were not detectable in the leukemic sample ( Table 1) . Given that, for example, a candidate mutation with 7% frequency was found in CDK9 using exome sequencing, we had hypothesized that this was a heterozygous mutation in the leukemic blasts. However, this was not validated with droplet digital PCR even after analysis of over 14 000 molecules of this region from the diagnostic DNA sample (Supplementary Figure S1 ). Although CDK9 is known to have a role in megakaryocyte maturation and to regulate both the Letters to the Editor cell cycle and transcription, further inspection of the exome data showed that the sequence quality was low at the mutant bases. Other unvalidated variant calls had low number of mutant reads, low mutant base quality or possible mapping problems. The droplet digital PCR validation demonstrated that a more stringent P-value, mutant base quality and read number filtration is necessary when analyzing challenging low-blast percentage samples.
The MMP8 mutation in our patient sample, a substitution from C to T on chr11:102592188, resulted in an amino-acid change MMP8 G189D . This mutation is predicted to be damaging and deleterious by SIFT and PROVEAN, 11, 12 respectively. This region is universally conserved in all vertebrates except in elephants and frogs (http://genome.uscs.edu/, 13 ). MMP8 encodes matrix metalloproteinase-8, which breaks down type I, II and III collagens in the extracellular matrix, and requires both calcium and zinc ions for activity. 14 The variation is located at a calcium ion binding site in the catalytic domain (Supplementary Figure S2) . To determine the effect of this mutation on enzymatic activity, we generated constructs containing either wild-type or mutant MMP8 and expressed them in HEK 293T cells. No difference was observed in the expression levels between the constructs (Figure 1f ). Type 1 collagen substrate gel zymography revealed significantly reduced proteolytic activity of the mutant compared with wild-type MMP8 (Figures 1g and h, P-value ¼ 0.017). To further assess whether MMP8 may have a role in AMKL leukemogenesis, we evaluated MMP8 expression in primary AMKL samples. Although RNA was not available from the index case, gene expression data from 41 pediatric AML cases including 16 cases of AMKL demonstrated eight of the 16 AMKL cases to have detectable MMP8 expression (Supplementary Figure S3 ). 7 All AMKL samples in this study had 490% purity, an important consideration given that MMP8 is known to be highly expressed in mature myeloid cells. Transcriptome sequencing was available for 14 of these AMKL cases and the sample with the highest signal by exon array also had significant levels of the MMP8 transcript by sequencing. In an independent cohort of 60 AMKL cases also analyzed by gene-expression profiling, a subset of patients had evidence of MMP8 expression. 15 Although the purity of these samples was extremely variable (12-94%), several samples with low purity (M7122, 12%; M7026, 28%) had low levels of MMP8 expression demonstrating that the variability in MMP8 expression cannot solely be due to myeloid cell contamination. Furthermore, there are cases with elevated expression that are relatively pure (M7040, 70%; M7072, 90%). Although the same mutation was not found in any of the samples, MMP8 is aberrantly expressed in a subset of AMKL cases. In addition, MMP8 mRNA is expressed in murine megakaryocyte-erythroid progenitors based on the ENCODE database (GSE40522). Given that MMP8 was the only candidate gene with 14% variation frequency in the exome sequencing, the patient had few cooperating mutations in coding regions, which might explain the excellent response to treatment and survival. In conclusion, we provide the first data identifying a novel somatic mutation that may provide a key insight to understanding the pathogenesis of RBM15-MKL1 in AMKL. The mechanisms underlying imatinib resistance in chronic myelogenous leukemia (CML) include BCR-ABL gene rearrangement, overexpression of Bcl-Abl tyrosine kinase fusion protein and activation of Bcr-Abl-independent pathways such as those of Src kinases. 1, 2 Although impressive therapeutic responses have been achieved with imatinib treatment, many patients fail to respond optimally due to innate or acquired resistance. 1, 2 The available treatments for these patients are limited and improved treatment options are urgently needed. In patients with Philadelphia chromosome-positive CML, tyrosyl phosphorylation of the Bcr-Abl oncoprotein enables binding to the Src homology-2 (SH2) domain of the adapter protein growth factor receptor-bound 2 (Grb2), thereby activating downstream signaling pathways, including the Ras/MAPK pathway, controlling cell proliferation. 3 Grb2 mutants missing one of its two SH3 domains impair cell transformation by Bcr-Abl, highlighting the importance of Grb2 interactors, such as SOS1, in oncogenic signaling. 4 These findings also suggest that Grb2 binding antagonists may provide an effective alternative or adjunct therapeutic strategy for CML patients resistant to imatinib. Small molecule Grb2 SH2 domain binding antagonists have been developed that are selective, potent and phosphatase resistant. 5 These have been shown to block the growth of tumorderived cells in culture as well as tumor angiogenesis and metastasis in mice. 3, 5, 6 We report here that TB03 ( Supplementary  Figure 1) , a member of this compound class, synergistically enhanced inhibition of K562 leukemia cell proliferation by imatinib (Figure 1 ). Treatment with TB03 or imatinib alone resulted in dose-dependent growth inhibition (Figures 1a and  b) ; when combined with TB03, imatinib activity was significantly enhanced (Figure 1b ). Combining imatinib with TB03 at a ratio of 1:100 was synergistic and achieved an ED 90 with a combination index (CI) of 0.774. At ratios of 1:50, 1:25, 1:12.5 and 1:6.25, all combinations were synergistic as indicated by CIs at ED 50 , ED 75 or ED 90 values (Supplementary Table 1 and Figure 1c ).
Flow cytometry experiments were performed to further characterize synergistic inhibition of K562 cell proliferation by the combination of imatinib and TB03. Analysis using annexin V-fluorescein isothiocyanate/propidium iodide double staining showed that treatment with either imatinib or TB03 alone did not affect apoptosis relative to the vehicle control group, but the combination of these two agents increased apoptosis by 450% (20% vs 36%; Figure 1d ), indicating functional complementation of distinct pro-apoptotic effects. Flow cytometry analysis using CellTrace Violet indicated that vehicle-treated K562 cells divided eight times in 72 h. Treatment with 0.25 or 2.5 mM imatinib alone resulted in 0.04% and 0.03% of cells reaching the eighth cell division, respectively, and treatment with 2 mM TB03 alone resulted in 0.08% of cells reaching the eighth cell division (Figure 1e ). Combined imatinib/TB03 treatments further reduced the number of cells reaching eight divisions: 0.02% for 2 mM TB03 plus 0.25 mM imatinib and 0.01% for 2 mM TB03 plus 2.5 mM imatinib; the latter combination represents an eightfold reduction in cell survival (Figure 1e ). Short-term analysis of cell cycle progression using Vybrant DyeCycle Green showed that imatinib treatment increased the G0/G1 population while decreasing the S and G2/M phase populations, consistent with cell cycle suppression (Figure 1f ). Treatment with TB03 alone had little effect, but combined TB03/imatinib treatment increased the number of cells in G0/G1 in a dose-dependent manner, with proportionately fewer cells reaching S and G2/M. The increased number of cells in sub-G1 phase with imatinib treatment relative to control (1.5% vs 4.7%) may reflect pro-apoptotic effects. Consistent with the complementation of apoptosis observed by annexin staining, TB03 plus imatinib further increased the number of cells in this phase in a dose-dependent manner, from 4.7 to 7% for imatinib:TB03 at a ratio 0.5:6.25 mM and from 4.7 to 11% for imatinib:TB03 at 0.5:12.5 mM (Figure 1f ). These results reinforce the hypothesis that TB03 alone inhibits only cell cycle progression, but enhances imatinib-induced apoptosis and cell cycle suppression, resulting in synergistic inhibition of K562 proliferation.
Cancer stem cells (CSCs) have become prime suspects for mediating resistance to therapy, disease relapse and progression. 7 High levels of aldehyde dehydrogenase (ALDH) activity have been recognized as a CSC marker in many cancers, including leukemia. 8 The effects of imatinib, TB03 and combined imatinib/TB03 treatment on a putative leukemia stem cell subpopulation of K562 was investigated by flow cytometry using ALDEFLUOR, which provides a fluorescent ALDH reaction product to identify stem and progenitor cells by ALDH activity. Among vehicletreated K562 cells 11.4% were ALDH þ , this was unaltered by TB03 treatment but decreased to 8.9% and 2.7% with imatinib treatment at 0.25 and 25 mM, respectively (Supplementary Figure 2 ). When combined with TB03 (20 mM), imatinib at 0.25 and 25 mM concentrations further reduced the ALDH þ K562 population to 5.0% and 1.8%, respectively (Supplementary Figure 2) . To our knowledge, this is the first evidence of leukemia Accepted article preview online 31 October 2013; advance online publication, 22 November 2013
